Tigatuzumab
Tigatuzumab (CS-1008) is a monoclonal antibody for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer has been completed, Phase II trials for colorectal cancer and non-small cell lung cancer are running, and a study for ovarian cancer has been approved.